Accessibility links
Glaxo-Wellcome Responds Steven LaFon is the Associate Director of the Anti-Viral Clinical research for Glaxo-Wellcome. He says he empathizes with Getty, and that the company's researchers are working as fast as they can to get the drug 15-92 to the marketplace. He says although the results of trials have been very encouraging, it is still in the very early stages of the approval and marketing process.

All Things Considered

Glaxo-Wellcome Responds

Heard on All Things Considered

Glaxo-Wellcome Responds

Listen · 2:47
  • Download
  • <iframe src="https://www.npr.org/player/embed/1057809/57809" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Steven LaFon is the Associate Director of the Anti-Viral Clinical research for Glaxo-Wellcome. He says he empathizes with Getty, and that the company's researchers are working as fast as they can to get the drug 15-92 to the marketplace. He says although the results of trials have been very encouraging, it is still in the very early stages of the approval and marketing process.